Forsta AP Fonden Sells 5,300 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Forsta AP Fonden decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 392,100 shares of the biopharmaceutical company's stock after selling 5,300 shares during the quarter. Forsta AP Fonden's holdings in Gilead Sciences were worth $36,218,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. State Street Corp raised its holdings in Gilead Sciences by 1.4% in the 3rd quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company's stock valued at $5,044,795,000 after acquiring an additional 841,776 shares in the last quarter. Wellington Management Group LLP raised its holdings in Gilead Sciences by 50.9% in the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock valued at $2,900,921,000 after acquiring an additional 11,665,593 shares in the last quarter. FMR LLC raised its holdings in Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company's stock valued at $2,780,329,000 after acquiring an additional 14,680,161 shares in the last quarter. Geode Capital Management LLC raised its holdings in Gilead Sciences by 2.1% in the 3rd quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company's stock valued at $2,302,119,000 after acquiring an additional 574,421 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Gilead Sciences by 3.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 7,752,975 shares of the biopharmaceutical company's stock worth $650,009,000 after buying an additional 224,960 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now owns 138,919 shares of the company's stock, valued at $12,886,126.44. This trade represents a 64.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the sale, the director now directly owns 8,920 shares in the company, valued at $815,198.80. This represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 456,234 shares of company stock worth $42,130,461. Corporate insiders own 0.16% of the company's stock.

Gilead Sciences Trading Up 1.9 %

Shares of NASDAQ:GILD traded up $1.74 during midday trading on Wednesday, hitting $95.59. The company had a trading volume of 5,585,554 shares, compared to its average volume of 6,797,380. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The stock has a market cap of $119.13 billion, a price-to-earnings ratio of 1,062.11, a PEG ratio of 1.31 and a beta of 0.18. The firm has a fifty day simple moving average of $92.00 and a 200 day simple moving average of $85.44.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company's revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.29 earnings per share. On average, analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Wells Fargo & Company increased their target price on Gilead Sciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. Leerink Partnrs raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Monday, October 21st. Morgan Stanley raised Gilead Sciences from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $87.00 to $113.00 in a report on Friday, January 10th. Bank of America reissued a "buy" rating and issued a $109.00 target price on shares of Gilead Sciences in a report on Tuesday, December 10th. Finally, Barclays increased their target price on Gilead Sciences from $84.00 to $95.00 and gave the stock an "equal weight" rating in a report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $98.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.